Spirox Inc.
Treating poor nasal breathers simply and non-surgically
This article was originally published in Start Up
Executive Summary
Faced with the large unmet clinical need of people with chronic nasal obstruction, an ENT physician formed Spirox to develop a non-surgical implant to restore the nasal valve. The ultimate goal is to develop a 15-minute procedure that ENTs can perform in their office to help patients breathe better.
You may also be interested in...
Companies See Opportunities In Expanding ENT Market
Competition breeds innovation, and the ear, nose, and throat (ENT) market, once a fairly quiet arena, is now positioned to host some spirited activity that should lead to new technologies. Several large device manufacturers have recently moved into the ENT space, and the sinus treatment segment of the market has become one of the focal points for emerging competitors, as companies work toward less-invasive treatment options.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.